Cetuximab is a chimeric monoclonal IgG1 antibody directed against extracellular domain of EGFR that in clinical studies was demonstrated to exert anticancer effect and increase tumor cell sensitivity to radiotherapy in GB [92]. The gene discussed is EGFR; the disease is neoplasm.